Operational Strength Contrasts With Regulatory Setbacks

Sarepta Therapeutics finds itself at a pivotal crossroads as it transitions from the S&P MidCap 400 to the S&P SmallCap 600 index today. While this technical move is expected to generate approximately $50 million in new institutional capital through mandatory portfolio adjustments by passive funds, the company continues to navigate significant regulatory headwinds that cloud its fundamental outlook.

Despite facing substantial challenges, Sarepta delivered impressive second-quarter 2025 results that surpassed Read more...